My take is that these guys need to focus, do less, deliver more and need robust clinical data to have any chance of success. Sirtex got a lucky break in 1997 with their clinical trial when FDA were less demanding on data / trial design and got US appoval for CRC. It was the US market that made Siretx so valuable. ROW was minimal. Nordion/Therasphere missed that FDA regulatory window and it took them 10/15 years to catch up after spending millions on clinical trials that took years to recruit and it was not until they had BTG/Boston cash behind them and made a success of the US that they started to fly. Both these guys where in big oncology spaces, liver/colorectal vs panc.
OSL Price at posting:
0.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)